The FDA gave the drug a 1C rating, meaning that it found little difference between felodipine and the drugs already approved for the same use.In 1994 Astra AB and Merck changed their partnership to a joint venture called Astra Merck, and in 1998 Astra (by that time, AstraZeneca)  bought out Mercks rights in the joint venture.The first generics became available in Sweden in 2003 and in the US in 2004.: 155 In April 2016, AstraZeneca announced that they were selling the right to market felodipine in China to China Medical System Holdings for $310 million; AZ would continue to manufacture the drug. Society and culture
As of 2016, felodipine was marketed under many brand names worldwide: Auronal, Cardioplen, Catrazil, Dewei, Dilahex, Enfelo, Erding, Fedil, Fedisyn, Feldil, Felicipin, Felo, Felocard, Felocor, Feloday, Felodil, Felodin, Felodip, Felodipin, Felodipina, Felodipine, Felodipino, Felodistad, Felogard, Felohexal, Felop, Felopine, Felostad, Feloten, Felotens, Felpin, Flodicar, Flodil, Keliping, Keydipin, Lodistad, Modip, Munobal, Nirmadil, Parmid, Penedil, Perfudal, Phelop, Phenodical, Plendil, Plentopine, Polo, Presid, Preslow, Prevex, Renedil, Sistar, Splendil, Stapin, Topidil, Vascalpha, Versant, and XiaoDing.The combination of felodipine and candesartan was marketed as Atacand.The combination of felodipine and ramipril was marketed as Delmuno, Tazko, Triacor, Triapin, Triasyn, Tri-Plen, Unimax, and Unitens.The combination of felodipine and enalapril was marketed as Lexxel.The combination of felodipine and metoprolol was marketed as Logimat, Logimax, and Mobloc. == References ==
Laurence–Moon syndrome (LMS) is a rare autosomal recessive genetic disorder associated with retinitis pigmentosa, spastic paraplegia, and mental disabilities. Signs and symptoms
Intellectual disability, hexadactyly, central diabetes insipidus, blindness (usually by 30 years due to central retinal degeneration). Genetics
LMS is inherited in an autosomal recessive manner. This means the defective gene responsible for the disorder is located on an autosome, and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder. Diagnosis
The syndrome was originally thought to have five cardinal features (and recently a sixth was added), on the basis of which a diagnostic criterion was developed:
4 primary features or 3 primary features and 2 secondary features must be present. The primary features are:
1. Polydactyly
2. Rod-cone dystrophy
3. Learning disabilities
4. Obesity
5. Hypogonadism in males
6. Renal abnormalities
While the secondary features are stated to be as:
1. Speech disorder and/or developmental delay
2. Ophthalmic abnormalities other than rod-cone dystrophy (strabismus, cataract, astigmatism etc.) 3. Brachydactyly or Syndactyly
4. Polyuria and/or polydipsia (nephrogenic diabetes insipidus)
5. Ataxia, poor coordination, imbalance
6. Mild spasticity (especially lower limbs)
7. Diabetes mellitus
8. Dental crowding, hypodontia, small roots, high arched palate
9. Congenital heart disease
10. Hepatic fibrosis

Treatment
There is no cure to LNMS. However, symptomatic treatment is often provided. The patients with LNMS often experience ataxia, spasticity and contractures, restricting their movements and daily activities.